ABOUT KINDRED

Kindred Capital is a seed and early stage venture firm focusing on European technology companies, founded in 2015.

Based in London, Kindred invests in entrepreneurs building globally ambitious businesses. The firm's five General Partners all have founding, operating and investing experience, and collectively they backed more than 100 companies before founding Kindred.

Uniquely, Kindred shares the upside of the fund with the entrepreneurs they back. This model of Equitable Venture has led to over 70 founders co-owning carry in the fund.

ABOUT THE FOUNDERS

Kindred was founded by Leila Zegna and Tracy Doree in 2015 and today has five General Partners: Leila Zegna, Mark Evans, Chrys Chrysanthou, Maria Palma and John Cassidy.

Leila Zegna
Leila was on the founding team of Genapsys, a gene sequencing startup in Silicon Valley. She was an active angel investor before founding Kindred in 2015. Leila has previously been GM of Plum District in San Francisco, Endeavor Fellow in Argentina, Supply Chain manager at Innocent Drinks in London, and a consultant at Bain in New York.

Mark Evans
Mark has been a VC investor for 20 years, starting in 2002 as a Partner in Benchmark Europe, which became Balderton Capital in 2008. Before this, Mark was the CEO of a US software services company, Entrepreneur in Residence at Benchmark Capital in Menlo Park and latterly spent 15 years working for Goldman Sachs in Europe, Asia and the US.

Chrys Chrysanthou
Chrys has been an investor at Notion and Accel Partners in London. He previously led BD for AWS in Europe, Middle East and Africa, building relationships with seed and growth funds, and the broader tech ecosystem. Chrys was on the founding team at Living PlanIT, a B2B company enabling the development of intelligent and sustainable urban-scale environments, and led services-related investments and acquisitions at Cisco.

Maria Palma
Maria is the latest addition to the Kindred partnership. She is joining Kindred from NY-based VC fund RRE, where she spent five years, both building their platform team from scratch and leading investments into some of their most exciting break-out companies. Prior to that she had a decade-long operating career spanning roles in startups and large corporations.

John Cassidy
John is an entrepreneur with dual expertise in cancer biology and financial economics. He has over 10 years’ experience in drug development; spanning academia (University of Cambridge), industry (MedImmune) and start-ups. He holds a Masters in Pharmacology (1st Class; top UK graduate) from the University of Glasgow, a PhD in Functional Genomics from the University of Cambridge, and has recently completed an MBA focussed on health economics. In 2018 John was honoured on the Forbes 30 Under 30 (Europe) list for his contributions to biotechnology and in 2020 became the youngest Fellow of the Royal Society of Biology (FRSB).

CONNECT WITH KINDRED

WEBSITE      TWITTER

PORTFOLIO HIGHLIGHTS